What new treatments for HER2-Positive Breast Cancer are being developed in 2026
New HER2-Positive Breast Cancer Treatments in Development
I appreciate your question about emerging treatments for HER2-positive breast cancer. However, I need to be transparent about what I can tell you based on current evidence.
What I Can Share
The medical guidelines and resources available to me don't contain specific information about HER2-positive breast cancer treatments in development for 2026. This is partly because:
- Treatment development moves quickly - New drugs and combinations are constantly being studied, and what's in development today may change significantly by 2026
- My sources have limitations - While I have access to educational webinars and current guidelines, they don't include detailed pipelines of future treatments
What IS Currently Standard for HER2-Positive Breast Cancer
According to NCCN (National Comprehensive Cancer Network) Guidelines, current HER2-positive breast cancer treatment typically includes:
- HER2-targeted therapies like trastuzumab (Herceptin) and pertuzumab (Perjeta)
- Tyrosine kinase inhibitors like lapatinib and tucatinib
- Antibody-drug conjugates like T-DM1 (Kadcyla) and fam-trastuzumab deruxtecan (Enhertu)
- Combinations of these with chemotherapy or hormone therapy depending on stage and receptor status
Where to Find Information About Emerging Treatments
For the most current information about treatments in development:
- ClinicalTrials.gov - Search for "HER2-positive breast cancer" to see active clinical trials
- ASCO (American Society of Clinical Oncology) - Publishes annual updates on emerging therapies
- American Cancer Society - Maintains current treatment information
- Your oncologist - Can discuss what's on the horizon for your specific situation
Questions to Ask Your Care Team
- Are there any new HER2-targeted therapies in clinical trials that might be appropriate for my specific case?
- What emerging treatment combinations are showing promise in recent studies?
- Should I consider participating in a clinical trial for a newer HER2-directed therapy?
- How do you stay updated on new treatment developments for HER2-positive breast cancer?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated May 23, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for Her__positive_breast_cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Her__positive_breast_cancer
- What happens when HER2-Positive Breast Cancer treatment stops working
- Should I switch cancer centers for my HER2-Positive Breast Cancer treatment
- What are treatment options when HER2-Positive Breast Cancer comes back
- When should I start treatment for HER2-Positive Breast Cancer vs watchful waiting
- How do I appeal an insurance denial for HER2-Positive Breast Cancer treatment
- What complementary therapies are safe alongside HER2-Positive Breast Cancer treatment
- How do I decide between clinical trial vs standard treatment for HER2-Positive Breast Cancer
- Does Medicare cover HER2-Positive Breast Cancer treatment including clinical trials